trending Market Intelligence /marketintelligence/en/news-insights/trending/tNtD6awFPubtw3DWl5UJTg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

US FDA extends review period for BioMarin's phenylketonuria drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

US FDA extends review period for BioMarin's phenylketonuria drug

BioMarin Pharmaceutical Inc. said the U.S. Food and Drug Administration extended the review period of the company's application for pegvaliase, used to treat the genetic disorder phenylketonuria.

The company said the U.S. regulator extended the Prescription Drug User Fee Act, or PDUFA, goal date for pegvaliase by three months to May 28, 2018. BioMarin added that due to the Memorial Day weekend, the action goal date will be May 25, 2018.

BioMarin said the FDA required additional time to complete the review.

Phenylketonuria is an inherited disorder that increases the levels of phenylalanine, an amino acid, in the blood.

In August, the regulator granted priority review to the company's application for pegvaliase. However, the agency had requested additional chemistry, manufacturing and controls information from BioMarin, which the company expected that when submitted, would result in a three-month extension of the PDUFA date.